Century Therapeutics, Inc. Variable Lease, Cost
Century Therapeutics, Inc. (IPSC) reported Variable Lease, Cost of $845.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-12
- Century Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $845.00K, a 16.55% increase year-over-year.
- Century Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $1.12M, a 68.83% increase year-over-year.
- Century Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $640.00K, a 6.98% decline year-over-year.
- Century Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $697.00K, a 3.57% increase year-over-year.
- Century Therapeutics, Inc. variable lease, cost for fiscal 2025 was $2.73M, a 4.93% increase from fiscal 2024.
- Century Therapeutics, Inc. variable lease, cost for fiscal 2024 was $2.60M, a 85.17% increase from fiscal 2023.
- Century Therapeutics, Inc. variable lease, cost for fiscal 2023 was $1.40M, a 11.26% increase from fiscal 2022.
- Century Therapeutics, Inc. variable lease, cost for fiscal 2022 was $1.26M, a 77.86% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $845.00K 10-Q · filed 2026-08-12 | $1.97M 10-Q · filed 2026-08-12 | $2.61M derived: sum of 3 quarters · filed 2026-08-12 | $3.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.12M 10-Q · filed 2026-05-13 | $1.76M derived: sum of 2 quarters · filed 2026-05-13 | $2.46M derived: sum of 3 quarters · filed 2026-05-13 | $3.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.34M derived: sum of 2 quarters · filed 2026-03-12 | $2.06M derived: sum of 3 quarters · filed 2026-08-12 | $2.73M 10-K · filed 2026-03-12 |
| 2025-09-30 | $697.00K 10-Q · filed 2025-11-13 | $1.42M derived: sum of 2 quarters · filed 2026-08-12 | $2.09M 10-Q · filed 2025-11-13 | $2.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $725.00K 10-Q · filed 2026-08-12 | $1.39M 10-Q · filed 2026-08-12 | $2.08M derived: sum of 3 quarters · filed 2026-08-12 | $2.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $664.00K 10-Q · filed 2026-05-13 | $1.35M derived: sum of 2 quarters · filed 2026-05-13 | $2.02M derived: sum of 3 quarters · filed 2026-05-13 | $2.81M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $688.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.36M derived: sum of 2 quarters · filed 2026-03-12 | $2.15M derived: sum of 3 quarters · filed 2026-03-12 | $2.60M 10-K · filed 2026-03-12 |
| 2024-09-30 | $673.00K 10-Q · filed 2025-11-13 | $1.46M derived: sum of 2 quarters · filed 2025-11-13 | $1.91M 10-Q · filed 2025-11-13 | $2.32M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $786.00K 10-Q · filed 2025-08-14 | $1.24M 10-Q · filed 2025-08-14 | $1.64M derived: sum of 3 quarters · filed 2025-08-14 | $2.12M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $450.00K 10-Q · filed 2025-05-15 | $858.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.33M derived: sum of 3 quarters · filed 2025-05-15 | $1.73M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $882.00K derived: sum of 2 quarters · filed 2025-03-19 | $1.28M derived: sum of 3 quarters · filed 2025-03-19 | $1.40M 10-K · filed 2025-03-19 |
| 2023-09-30 | $474.00K 10-Q · filed 2024-11-05 | $870.00K derived: sum of 2 quarters · filed 2024-11-05 | $995.00K 10-Q · filed 2024-11-05 | $1.42M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $396.00K 10-Q · filed 2024-08-08 | $521.00K 10-Q · filed 2024-08-08 | $942.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.25M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $125.00K 10-Q · filed 2024-05-09 | $546.00K derived: sum of 2 quarters · filed 2024-05-09 | $849.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.09M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $724.00K derived: sum of 2 quarters · filed 2024-03-14 | $965.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.26M 10-K · filed 2024-03-14 |
| 2022-09-30 | $303.00K 10-Q · filed 2023-11-09 | $544.00K derived: sum of 2 quarters · filed 2023-11-09 | $840.00K 10-Q · filed 2023-11-09 | $993.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $241.00K 10-Q · filed 2023-08-09 | $537.00K 10-Q · filed 2023-08-09 | $690.00K derived: sum of 3 quarters · filed 2023-08-09 | $809.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $297.00K 10-Q · filed 2023-05-11 | $449.00K derived: sum of 2 quarters · filed 2023-05-11 | $568.00K derived: sum of 3 quarters · filed 2023-05-11 | $734.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $271.00K derived: sum of 2 quarters · filed 2023-03-16 | $437.00K derived: sum of 3 quarters · filed 2023-03-16 | $709.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $119.00K 10-Q · filed 2022-11-10 | $285.00K derived: sum of 2 quarters · filed 2022-11-10 | $557.00K 10-Q · filed 2022-11-10 | $618.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $166.00K 10-Q · filed 2022-08-11 | $438.00K 10-Q · filed 2022-08-11 | $499.00K derived: sum of 3 quarters · filed 2022-08-11 | $543.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $272.00K 10-Q · filed 2022-05-16 | $333.00K derived: sum of 2 quarters · filed 2022-05-16 | $377.00K derived: sum of 3 quarters · filed 2022-05-16 | $403.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $105.00K derived: sum of 2 quarters · filed 2022-03-17 | $131.00K derived: sum of 3 quarters · filed 2022-03-17 | $131.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $44.00K 10-Q · filed 2021-11-10 | $70.00K derived: sum of 2 quarters · filed 2021-11-10 | $70.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $26.00K 10-Q · filed 2021-08-12 | $26.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |